Kenvue Inc. (KVUE)
| Market Cap | 30.97B |
| Revenue (ttm) | 15.01B |
| Net Income (ttm) | 1.43B |
| Shares Out | 1.92B |
| EPS (ttm) | 0.75 |
| PE Ratio | 21.59 |
| Forward PE | 14.93 |
| Dividend | $0.83 (5.14%) |
| Ex-Dividend Date | Nov 12, 2025 |
| Volume | 204,203,687 |
| Open | 17.07 |
| Previous Close | 14.37 |
| Day's Range | 16.14 - 17.18 |
| 52-Week Range | 14.02 - 25.17 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 20.23 (+25.34%) |
| Earnings Date | Nov 3, 2025 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]
Financial Performance
In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $20.23, which is an increase of 25.34% from the latest price.
News
The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker
Mike Hsu aims to stoke the consumer company's growth by veering into Kenvue's higher-margin but risky health products.
Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'
Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump ...
Kenvue's legal risks loom over planned acquisition by Kimberly-Clark
Kimberly-Clark said on Monday it plans to acquire Band-Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising qu...
S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue
A linkup with an artificial intelligence player helped power shares of a top cloud-computing services company higher Monday, while an acquisition in the consumer goods space sent the two stocks on div...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.
NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kenvue Inc. (NYSE: KVUE) and its board of directors concerning the proposed acquisition ...
Kimberly-Clark's $50 billion leap into health and beauty tests investor faith
Kimberly-Clark's nearly $50 billion offer for Tylenol maker Kenvue is a risky bet that the world's biggest consumer market, the United States, will keep growing even as lower-income shoppers trim thei...
KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
It's been a tough few weeks for the consumer health company Kenvue, after President Trump publicly spread unproven claims about Tylenol, one of its core subsidiary brands. Today, though, it seems like...
Explainer: Is Tylenol safe to take during pregnancy?
There is no firm evidence of a link between the use of the drug and autism.
Kenvue deal could double Kimberly-Clark stock's multiple: find out more
Kenvue Inc (NYSE: KVUE) opened about 20% higher this morning after Kimberly-Clark (NYSE: KMB) announced a $40 billion acquisition of the consumer health company. According to its press release, it wil...
Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger
The deal would bring Huggies, Kleenex, Band-Aid, Neutrogena, and Tylenol under one roof, creating a consumer staples giant. Transcript: Caroline Woods: Big brands and big money - Kimberly-Clark is buy...
Kimberly-Clark Is Buying Tylenol Maker Kenvue for Nearly $49B. Here's What You Need to Know
Kenvue (KVUE) shares skyrocketed in early trading Monday after Kleenex and Cottonelle maker Kimberly-Clark (KMB) said it's buying the Tylenol maker in a $48.7 billion deal.
Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal
Kimberly-Clark agreed to buy Kenvue in a deal worth roughly $40 billion in a combination that could create a company with $32 billion in revenue and allow it to surpass Unilever to become the second-b...
Kimberly-Clark buys Tylenol maker Kenvue in a cash and stock deal for $48.7 billion
Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.
Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day.
D.E. Shaw, one of the Tylenol-maker's largest shareholders, stood to lose over $200 million but is now expected to break even on its bet.
Kimberly-Clark agrees to buy Tylenol owner Kenvue, creating consumer staples giant
Kimberly-Clark announced Monday it's struck an agreement to buy Kenvue in a deal valued at $48.7 billion. CNBC's David Faber breaks down the details.
Another Big Earnings Week Ahead, KVUE Soars on KMB $48.7B Deal
While all the Mag 7 but Nvidia (NVDA) reported their quarterly earnings, 135 SPX companies and 25 NDX companies are on the docket this week. Kevin Hincks points to Palantir's (PLTR) report after Monda...
Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger
Kleenex maker's deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny
Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Deal
Kimberly-Clark will acquire Kenvue in a deal valued at nearly $49 billion, both companies announced Monday, combining the maker of Huggies diapers and Kleenex with the owner of Tylenol, which has face...
Kimberly-Clark to acquire Tylenol owner Kenvue in $48.7 billion deal
CNBC's David Faber joins 'Squawk Box' with the latest news.
Kimberly-Clark to buy embattled Tylenol maker Kenvue in a deal valued at more than $48 billion
Kenvue's stock, which had hit a record low in recent weeks, was headed for its best day ever while Kimberly-Clark's stock tumbled.
Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark's $48.7-billion deal
Kenvue missed Wall Street estimates for third-quarter sales on Monday, while it also announced its acquisition by Kimberly-Clark for about $48.7 billion.
Kimberly-Clark agrees to buy Kenvue in $48.7 billion deal, creating consumer staples giant
Kimberly-Clark announced Monday it's struck an agreement to buy Kenvue in a deal valued at $48.7 billion. The combined company would bring together brands like Huggies and Kleenex with the likes of Ba...
Kimberly-Clark to Buy Kenvue in Deal That Values Tylenol Maker at $48.7 Billion
Kimberly-Clark will buy Kenvue for cash and stock.
Kimberly-Clark to Buy Tylenol Maker Kenvue
The $48.7 billion deal, which includes debt, combines the maker of Huggies diapers with the owner of the painkiller maker.